Multivariate analysis competing risks end points
| . | NRM . | Relapse . | aGVHD 2-4 . | aGVHD 3-4 . | cGVHD . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Analysis group (Ref., 10/10 MUD), PT-CY Haplo | 1.62 | 1.36-1.94 | <.001 | 0.83 | 0.69-0.99 | .038 | 1.46 | 1.25-1.71 | <.001 | 1.74 | 1.37-2.20 | <.001 | 1.30 | 1.11-1.51 | .001 |
| Patient age (Ref., 18-19), y | |||||||||||||||
| 20-29 | 1.16 | 0.59-2.27 | .673 | — | — | — | — | ||||||||
| 30-39 | 1.23 | 0.63-2.42 | .544 | — | — | — | — | ||||||||
| 40-49 | 2.09 | 1.10-3.98 | .024 | — | — | — | — | ||||||||
| 50-59 | 2.43 | 1.28-4.59 | .006 | — | — | — | — | ||||||||
| 60-69 | 3.19 | 1.69-6.02 | <.001 | — | — | — | — | ||||||||
| 70-79 | 4.21 | 2.21-8.03 | <.001 | — | — | — | — | ||||||||
| EBMT stage (Ref., early) | |||||||||||||||
| Intermediate | 1.27 | 1.12-1.43 | <.001 | 1.13 | 1.00-1.27 | .050 | — | — | 0.90 | 0.81-1.00 | .051 | ||||
| Advanced | 1.41 | 1.27-1.57 | <.001 | 1.78 | 1.61-1.97 | <.001 | — | — | 0.75 | 0.67-0.82 | <.001 | ||||
| KPS (Ref., ≥80), <80 | 2.10 | 1.81-2.43 | <.001 | — | — | — | 0.85 | 0.71-1.01 | .065 | ||||||
| Year of HSCT (Ref., 2010-2015), 2016-2020 | 0.87 | 0.76-1.00 | .058 | 0.92 | 0.83-1.01 | .085 | 0.96 | 0.86-1.07 | .476 | 1.02 | 0.85-1.21 | .849 | 0.83 | 0.76-0.92 | <.001 |
| Donor age (Ref., 18-19), y | |||||||||||||||
| 20-29 | 1.48 | 1.01-2.16 | .044 | — | — | — | — | ||||||||
| 30-39 | 1.58 | 1.08-2.31 | .019 | — | — | — | — | ||||||||
| 40-49 | 2.00 | 1.35-2.95 | .001 | — | — | — | — | ||||||||
| 50-59 | 2.15 | 1.41-3.28 | <.001 | — | — | — | — | ||||||||
| 60-99 | 1.50 | 0.63-3.58 | .361 | — | — | — | — | ||||||||
| HCT-CI score (Ref., 0), ≥1 | 1.43 | 1.27-1.61 | <.001 | 0.85 | 0.77-0.93 | .001 | 1.15 | 1.03-1.27 | .010 | 1.27 | 1.07-1.50 | .005 | 0.87 | 0.80-0.96 | .004 |
| CMV Pat. Don. (Ref., neg. neg.) | |||||||||||||||
| Neg. pos. | 1.03 | 0.86-1.22 | .775 | — | 1.01 | 0.86-1.19 | .865 | 0.86 | 0.66-1.13 | .285 | — | ||||
| Pos. neg. | 1.23 | 1.08-1.39 | .001 | — | 0.91 | 0.80-1.03 | .120 | 0.91 | 0.75-1.11 | .349 | — | ||||
| Pos. pos. | 1.06 | 0.95-1.17 | .326 | — | 0.94 | 0.85-1.04 | .259 | 1.00 | 0.86-1.17 | .954 | — | ||||
| Conditioning intensity (Ref., MAC), RIC | — | — | — | — | 1.14 | 1.05-1.24 | .003 | ||||||||
| Previous autologous Tx (Ref., no), yes | — | — | — | — | — | ||||||||||
| Stem cell source (Ref., PBSC), BM | — | — | — | 0.74 | 0.53-1.03 | .076 | 0.75 | 0.61-0.92 | .006 | ||||||
| Sex mismatch (Ref., no), yes | — | — | — | — | 1.10 | 0.96-1.25 | .165 | ||||||||
| . | NRM . | Relapse . | aGVHD 2-4 . | aGVHD 3-4 . | cGVHD . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Analysis group (Ref., 10/10 MUD), PT-CY Haplo | 1.62 | 1.36-1.94 | <.001 | 0.83 | 0.69-0.99 | .038 | 1.46 | 1.25-1.71 | <.001 | 1.74 | 1.37-2.20 | <.001 | 1.30 | 1.11-1.51 | .001 |
| Patient age (Ref., 18-19), y | |||||||||||||||
| 20-29 | 1.16 | 0.59-2.27 | .673 | — | — | — | — | ||||||||
| 30-39 | 1.23 | 0.63-2.42 | .544 | — | — | — | — | ||||||||
| 40-49 | 2.09 | 1.10-3.98 | .024 | — | — | — | — | ||||||||
| 50-59 | 2.43 | 1.28-4.59 | .006 | — | — | — | — | ||||||||
| 60-69 | 3.19 | 1.69-6.02 | <.001 | — | — | — | — | ||||||||
| 70-79 | 4.21 | 2.21-8.03 | <.001 | — | — | — | — | ||||||||
| EBMT stage (Ref., early) | |||||||||||||||
| Intermediate | 1.27 | 1.12-1.43 | <.001 | 1.13 | 1.00-1.27 | .050 | — | — | 0.90 | 0.81-1.00 | .051 | ||||
| Advanced | 1.41 | 1.27-1.57 | <.001 | 1.78 | 1.61-1.97 | <.001 | — | — | 0.75 | 0.67-0.82 | <.001 | ||||
| KPS (Ref., ≥80), <80 | 2.10 | 1.81-2.43 | <.001 | — | — | — | 0.85 | 0.71-1.01 | .065 | ||||||
| Year of HSCT (Ref., 2010-2015), 2016-2020 | 0.87 | 0.76-1.00 | .058 | 0.92 | 0.83-1.01 | .085 | 0.96 | 0.86-1.07 | .476 | 1.02 | 0.85-1.21 | .849 | 0.83 | 0.76-0.92 | <.001 |
| Donor age (Ref., 18-19), y | |||||||||||||||
| 20-29 | 1.48 | 1.01-2.16 | .044 | — | — | — | — | ||||||||
| 30-39 | 1.58 | 1.08-2.31 | .019 | — | — | — | — | ||||||||
| 40-49 | 2.00 | 1.35-2.95 | .001 | — | — | — | — | ||||||||
| 50-59 | 2.15 | 1.41-3.28 | <.001 | — | — | — | — | ||||||||
| 60-99 | 1.50 | 0.63-3.58 | .361 | — | — | — | — | ||||||||
| HCT-CI score (Ref., 0), ≥1 | 1.43 | 1.27-1.61 | <.001 | 0.85 | 0.77-0.93 | .001 | 1.15 | 1.03-1.27 | .010 | 1.27 | 1.07-1.50 | .005 | 0.87 | 0.80-0.96 | .004 |
| CMV Pat. Don. (Ref., neg. neg.) | |||||||||||||||
| Neg. pos. | 1.03 | 0.86-1.22 | .775 | — | 1.01 | 0.86-1.19 | .865 | 0.86 | 0.66-1.13 | .285 | — | ||||
| Pos. neg. | 1.23 | 1.08-1.39 | .001 | — | 0.91 | 0.80-1.03 | .120 | 0.91 | 0.75-1.11 | .349 | — | ||||
| Pos. pos. | 1.06 | 0.95-1.17 | .326 | — | 0.94 | 0.85-1.04 | .259 | 1.00 | 0.86-1.17 | .954 | — | ||||
| Conditioning intensity (Ref., MAC), RIC | — | — | — | — | 1.14 | 1.05-1.24 | .003 | ||||||||
| Previous autologous Tx (Ref., no), yes | — | — | — | — | — | ||||||||||
| Stem cell source (Ref., PBSC), BM | — | — | — | 0.74 | 0.53-1.03 | .076 | 0.75 | 0.61-0.92 | .006 | ||||||
| Sex mismatch (Ref., no), yes | — | — | — | — | 1.10 | 0.96-1.25 | .165 | ||||||||